// App-Quantinova.ai

836TiP : The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Researchers

Presenter

  • S.Chowdhury

Principal Investigators

  • J.Arranz Arija

  • G.Daugaard

  • K.Fizazi

  • E.Gez

  • A.Heidenreich

  • F.Joly Lobbedez

  • R.McDermott

  • A.S.Merseburger

  • J.M.Piulats Rodriguez

  • B.Sautois

  • S.Sridhar

  • C.N.Sternberg

  • S.Watkins

  • A.Simmons

  • S.Shetty

  • A.Golsorkhi

  • C.J.Ryan

  • H.Scher

Medical Centers

  • Urological Cancer, Guy’s Hospital & Sarah Cannon Research Institute, London, UK

  • Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

  • Medical Oncology Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain

  • Nephrology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

  • Groupe Uro-Genitologie, University of Paris Institut Gustave Roussy, Villejuif, France

  • Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

  • Klinik für Urologie, Universitätsklinikum Köln, Cologne, Germany

  • Dept. of Medical Oncology, Centre Francois Baclesse, Caen, France

  • Genito-Urinary Oncology, Tallaght & St. Vincent’s University Hospital and Cancer Trials Ireland, Dublin, Ireland

  • Urologic Oncology, Lübeck University Hospital, Lübeck, Germany

  • Medical Oncology Department, Institut Catala dOncologia, Barcelona, Spain

  • Hematology, University Hospital of Liege, Liege, Belgium

  • Division of Medical Oncology, Princess Margaret Hospital/University of Toronto, Toronto, ON, Canada

  • Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy

  • Clinical Science, Clovis Oncology, Inc., Boulder, CO, USA

  • Translational Medicine, Clovis Oncology, Inc., Boulder, CO, USA

  • Clinical Science, Clovis Oncology, Inc., Boulder, CO, USA

  • Clinical Science, Clovis Oncology, Inc., Boulder, CO, USA

  • Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Locations

  • United Kingdom

  • United States

  • Spain

  • Denmark

  • France

  • Israel

  • Germany

  • Ireland

  • Belgium

  • Canada

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Prostate specific antigen

  • Partner and localizer of BRCA2

  • RAD51 Paralog C

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Rucaparib

  • Docetaxel

  • Androgen Tear

  • ribose

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved